

Bivariate analysis of new second generation antipsychotic prescriptions by any cardio-metabolic disorder

Variable	Any Cardio-metabolic disorder		X ²	df	p-value		
	Yes					No	
	n=1650 (63%)	n=963 (37%)				n	(%)
Medication			13.29	5	.021		
Olanzapine	242 (15)	167 (17)					
Quetiapine	745 (45)	471 (49)					
Risperidone oral	297 (18)	138 (14)					
LAI Risperidone	20 (1)	14 (2)					
Aripiprazole	264 (16)	126 (13)					
Ziprazidone	82 (5)	47 (5)					
Reasons							
Intolerance	192 (68)	91 (32)	4.21	1	.040		
Less EPS	210 (61)	133 (39)	.21	1	.642		
Less TD Risk	157 (64)	88 (36)	.36	1	.548		
Less Akathisia	75 (58)	54 (42)	1.02	1	.311		
Less Sedation	89 (61)	58 (40)	.21	1	.644		
Efficacy	694 (62)	427 (38)	.17	1	.678		
Treatment of TD	9 (64)	5 (36)	.02	1	.880		
Sleep/Sedation	431 (61)	276 (39)	.83	1	.362		
Patient Preference	442 (62)	270 (38)	.03	1	.867		